PMA device
Prospera Spinal Cord Stimulation (SCS) System
Biotronik Nro, Inc. · Stimulator, Spinal-Cord, Totally Implanted For Pain Relief (LGW, Class III) · First FDA decision Mar 31, 2023, newest Jun 25, 2025Chronic pain
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
4
Naming "Prospera"
MAUDE reports
266
Brand "Prospera", since 2015
PubMed studies
63
Mentioning "Prospera"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Prospera Spinal Cord Stimulation (SCS) System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- Prospera Spinal Cord Stimulation (SCS) System, Resilience Percutaneous Lead, HomeStream Remote ManagementPMA supplement
P210037-S011 · Decided Jun 25, 2025 · 82 days after receipt · Normal 180 Day Track
Device type: Stimulator, spinal-cord, totally implanted for pain relief (LGW) · Neurology & Neurosurgery
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Prospera", any status and sponsor, newest update first.
- A First in Human Feasibility Study to Evaluate the Safety and Effectiveness of the BIOTRONIK Prospera SCS System With HomeStream Remote ManagementActive, not recruiting
Biotronik, Inc.Not on our public-company list
NCT04683718 · 60 participants (planned) · Start Sep 20, 2021 · Primary completion Aug 21, 2025
Device: Permanent implant of a BIOTRONIK Prospera SCS (Spinal Cord Stimulation) System with HomeStream Remote Management · For: Chronic Low-back Pain; Chronic Leg Pain
Sites: Broadmeadow, Australia; Hurstville, Australia; Wahroonga, Australia · 5 sites in all
3 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Prospera", and for the whole product code for context.
This brand
266 reports: 16 malfunction, 250 injury, 0 death
Whole product code LGW
301,867 reports: 79,174 malfunction, 220,939 injury, 1,642 death
Newest reports for this brand
- Prospera IPGInjury
3027063190-2026-00410 · Received Oct 27, 2026 · Event dated Aug 7, 2026
Device type: Stimulator, Spinal-Cord, Totally Implanted For Pain Relief (LGW)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Inadequate Pain Relief
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Prospera"[tiab]. The summary above synthesizes these.
- [Not Available].
Rivera-Dommarco JA, Cuevas-Nasu L, Bonvecchio-Arenas A, et al. · Salud Publica Mex · 2024English Abstract
- A Pons Prospera for Child Neurology.
Asato MR · Neurology · 2024Editorial
- Evaluation of a collaborative model between managed care and affordable housing on acute care costs.
Tsai J, Rajan S, Truong C, et al. · Am J Manag Care · 2024Research Support, Non-U.S. Gov't
- [Not Available].
De la Cruz-Góngora V, Shamah-Levy T, Villalpando S, et al. · Salud Publica Mex · 2021
- [Not Available].
Vizuet Vega NI, Shamah Levy T, Gaona Pineda EB, et al. · Nutr Hosp · 2016
- Mexico's Prospera Program and Indigenous Women's Reproductive Rights.
Abarbanell L · Qual Health Res · 2020Research Support, Non-U.S. Gov't
- Manual therapy for the pediatric population: a systematic review.
Parnell Prevost C, Gleberzon B, Carleo B, et al. · BMC Complement Altern Med · 2019Systematic Review
- Tale of two assays: Comparison of modern donor-derived cell-free DNA technologies.
Hsi B, Van Zyl J, Alam K, et al. · JHLT Open · 2024
- Donor-Derived Cell Free DNA: Is It All the Same?
Melancon JK, Khalil A, Lerman MJ · Kidney360 · 2020
- PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy.
Nuebling G, Hensler M, Paul S, et al. · J Neurol · 2016Randomized Controlled Trial
- Effect of a conditional cash transference program on food insecurity in Mexican households: 2012-2016.
Saldivar-Frausto M, Unar-Munguía M, Méndez-Gómez-Humarán I, et al. · Public Health Nutr · 2022Research Support, Non-U.S. Gov't
- Donor-Derived Cell-Free DNA: Is It All the Same? The Jury Is Still Out.
Garg N · Kidney360 · 2020Editorial, Comment
Other devices of this type
Also filed under product code LGW.
- Precision Spinal Cord Stimulator (SCS) SystemsBoston Scientific Corp · PMA 2026
- Senza Spinal Cord Stimulation (SCS) SystemNevro Corporation · PMA 2025
- Saluda Medical Evoke SCS SystemSaluda Medical Pty, Ltd. · PMA 2026
- Master RestoreMedtronic Neuromodulation · PMA 2026
- RestoreMedtronic Neuromodulation · PMA 2025
- Genesis and Eon Family Neurostimulation (Ipg) SystemsAbbott Medical · PMA 2016
- Genesis Neurostimulation SystemAbbott Medical · PMA 2024
- Precision Spectra Spinal Cord Stimulator (SCS) SystemBoston Scientific Corp · PMA 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.